Background. Chimeric molecules comprising the A-chain of tissue-type plasminogen activator (t-PA) and the catalytic domain of urokinase-type plasminogen activator (u-PA) have intact enzymatic characteristics of u-PA, partial fibrin-binding properties of t-PA, and thrombolytic properties in animal models comparable with but not superior to those of single-chain u-PA (scu-PA). Deletion of the finger and growth factor domains (t-PA-AFE/scu-PA-e) in such chimeras further reduces their affinity for fibrin. Methods and Results. A detailed investigation of the thrombolytic potency and the pharmacokinetics of t-PA and u-PA chimeras was performed in quantitative animal models for thrombolysis. In hamsters with pulmonary embolism, in rabbits with jugular vein thrombosis, and in baboons with femoral vein thrombosis, the thrombolytic potency (percent lysis per milligram of compound administered per kilogram of body weight) of t-PA-AFE/scu-PA-e was significantly higher than that of recombinant scu-PA (rscu-PA, Saruplase) as shown by a maximal rate of 720±170% versus 45±5% lysis per milligram of compound per kilogram of body weight (mean±SEM,p<0.01) in hamsters, 210±18% versus 49±3% lysis per milligram of compound per kilogram of body weight (mean± SEM, p <0.01) in rabbits, and 310±73% versus 90±0.3% lysis per milligram of compound per kilogram of body weight (p<0.01) in baboons.
T Nhrombolytic therapy resulting in recanalizafor patients with acute myocardial infarction.' Curtion of occluded coronary arteries, preservarently, five plasminogen activators are used or are tion of left ventricular function, and reducunder clinical investigation for coronary arterial tion of mortality has become a preferred treatment thrombolysis in patients with acute myocardial infarction. These include streptokinase, acylated plas-and two-chain urokinase-type plasminogen activator (tcu-PA, urokinase).' Streptokinase activates circulating and fibrin-associated plasminogen relatively indiscriminately, causing plasminogen and a2-antiplasmin depletion and extensive systemic fibrinogen breakdown; it is only moderately efficacious in terms of coronary artery recanalization. rt-PA induces plasminogen activation more efficiently in the presence of fibrin than in its absence, whereby activation is relatively restricted to the vicinity of a blood clot.2 This results in more efficient clot lysis with much less activation of plasminogen in circulating blood. t-PA is composed of 527 amino acids and contains several structural/ functional domains: a fingerlike domain (F) including amino acids 4-50, an epidermal growth factor domain (E) comprising residues 50-87, two kringle domains (K1 and K2) comprising residues 87-176 and 176-262, and a serine protease domain including residues 276-527.3 4The fibrin specificity of t-PA is mainly due to its affinity for fibrin and to a markedly enhanced activation of plasminogen at the fibrin surface.5 Structures in t-PA responsible for its fibrin affinity are localized in its NH2-terminal region, probably in the fingerlike domain and in the second kringle.6 scu-PA also activates plasminogen more efficiently in the presence of fibrin, notwithstanding the fact that the mechanism of activation is different from that of t-PA.7 scu-PA is composed of 411 amino acids and also contains several structural/functional domains: an epidermal growth factor domain (E) including residues 9-45, a kringle region (K) comprising amino acids , and a serine protease domain comprising residues 159-411. 8, 9 The fibrin specificity of scu-PA is not dependent on the presence of the NH2-terminal 143 amino acids,10 whereas u-PA only displays fibrin specificity in the scu-PA form, in which the Lys158-Ile159 peptide bond is intact. 7 In comparative studies performed in patients with acute myocardial infarction, fibrin-specific t-PA and scu-PA have been shown to be more efficient for coronary thrombolysis than the nonfibrin-specific streptokinase. 11, 12 Still, many questions relating to the optimal use of these compounds and to the relation between thrombolytic efficacy and clinical benefit remain unanswered. 13 The fibrin specificity of t-PA and scu-PA is not as pronounced in humans as was anticipated from several animal models.12 Furthermore, both t-PA and scu-PA have a very short plasma half-life as a result of rapid hepatic clearance, whereby their therapeutic use probably requires continuous intravenous infusion of relatively large amounts of material (50-100 mg), which is time consuming and expensive. Therefore, the quest for thrombolytic agents with a higher thrombolytic potency, a higher specific thrombolytic activity, and/or a better fibrin selectivity remains open. One approach to the development of improved thrombolytic agents might consist of the production of chimeric proteins, which contain structures harboring the enzymatic activity of u-PA, linked to structures conferring fibrin affinity to the molecule. This approach has been investigated by several groups and recently reviewed by Krause, 14 Lijnen and Collen,15 and Haber et al. 16 u-PA-based chimeras have been produced by disulfide cross-linkage between the a-chain of plasmin and the (3-chain of urokinase17 or as recombinant DNA-derived chimeric molecules that combine parts of the NH2terminal sequence of t-PA or plasmin fused to the COOH-terminal protease region of u-PA. [18] [19] [20] [21] [22] [23] [24] Most of these recombinant enzymes were shown to be enzymatically active; some acquired fibrin affinity and some had a delayed clearance. Improved thrombolytic potency in in vivo models has thus far not been reported.
Chimeric molecules of t-PA and u-PA have been produced by expression of complementary DNA (cDNA) fragments of t-PA (encoding amino acids 1-67, 1-212, or 1-313, respectively3) spliced to cDNA fragments of scu-PA (encoding amino acids 136-411, 139-411, or 195-411, respectively8 ). These recombinant products had intact catalytic activities of scu-PA but had not acquired fibrin affinity of t-PA or an improved in vitro fibrin selectivity compared with scu-PA. 20, 25, 26 In a further development, two chimeric plasminogen activators (t-PA/u-PA-s and t-PA/u-PA-e) consisting of the NH2-terminal part of t-PA (amino acids 1-263 and 1-274, respectively) and the catalytic domain of scu-PA (amino acids 144-411 and 138-411, respectively) were obtained. These compounds retained the specific activity, catalytic efficiency, and in vitro fibrinolytic potency of u-PA (either in their single-chain or their two-chain forms) and partially acquired the fibrin affinity and fibrin stimulation of t-PA. '8,27 Intravenous infusion of t-PA/ scu-PA-s, t-PA/scu-PA-e, or scu-PA in a rabbit jugular vein thrombosis model resulted in very similar dose-response curves of clot lysis, indicating that combination of the fibrin-binding domains of t-PA with the catalytic domain of scu-PA, which endows the chimeric molecules with significant fibrin affinity, is not associated with an increased thrombolytic potency in vivo. 28 The structure/function relation between fibrin affinity and the thrombolytic potency of t-PA/u-PA chimeras was further investigated by domain deletion/substitution of the t-PA/scu-PA-e chimera. Deletion of F and E domains yielded t-PA-AFE/scu-PA-e, with a markedly reduced affinity for fibrin and lysine-Sepharose, whereas substitution of K1 by a second copy of K2 produced t-PA-AK1VK2/scu-PA-e, with increased affinity for fibrin and lysine-Sepharose. However, neither modification significantly altered the specific activity, catalytic efficiency for plasminogen activation, or fibrinolytic potency in an in vitro clot lysis system.29 Most surprising, on subsequent in vivo evaluation of the thrombolytic potency of these variants in a hamster pulmonary embolism model, t-PA-AFE/scu-PA-e but neither t-PA-AK,VK2/scu-PA-e nor the combination variant t-PA-AFEK1VK2/scu-PA-e had a markedly increased thrombolytic potency in vivo. This observation led to a more detailed investigation of 1218 Circulation Vol 84, No 3 September 1991 the pharmacokinetics and thrombolytic potency of these chimeras in quantitative and reproducible animal models for venous and arterial thrombolysis as summarized below.
Methods

Proteins
The t-PA/u-PA chimeras of the present study were purified and characterized as described in detail elsewhere. 18, 2729 Their main biochemical properties are summarized in Table 1 and their structures are schematically represented in Figure 1 .30,31 Saruplase (commercial recombinant scu-PA) was a gift from Grunenthal GmbH (Aachen, FRG) and Activase (commercial recombinant t-PA) was a gift from Genentech Inc. (South San Francisco, Calif.). Ridogrel, a combined thromboxane synthase inhibitor and prostaglandin endoperoxide receptor antagonist,32 was a gift from the Janssen Research Foundation (Beerse, Belgium).
Analytical Methods
Fibrinogen in plasma samples was determined with a clotting rate assay, a2-antiplasmin with a chromogenic substrate assay, t-PA-related or u-PA-related antigen with specific enzyme-linked immunosorbent assays (ELISAs) as described elsewhere,33 and activated partial thromboplastin times by routine laboratory assay. t-PA-AFE/scu-PA-e was determined using a radioimmunoassay34 or, in the dog experiments, a sandwich ELISA assay. The radioimmunoassay was a four-compartment assay consisting of sample or standard dilution, 1251-labeled t-PA-AFE/ scu-PA-e (20,000 cpm), rabbit antiserum raised against t-PA, and Sac-Cel (donkey anti-rabbit IgG, Wellcome Diagnostics). After 30 minutes of incubation, the radioisotope associated with the gel was determined.
Template bleeding times were measured before and at 10, 60, and 120 minutes after the bolus injection of t-PA-AFE/scu-PA-e in the dogs. The bleeding time incision was made using an automated spring-loaded device (Simplate-II, General Diagnostics, Morris Plains, N.J.) applied to the volar surface of the foreleg. The region of the incision site was washed, shaved, and dried before the first bleeding time.
In the dog studies, platelet counting was performed on an automatic cell counter (Sequoia Turner Corporation, Mountain View, Calif.). Platelet aggregation induced with ADP or the combination of arachidonic acid and epinephrine was performed within 1 hour after blood sampling using a standard aggregometer (Chronolog Corporation, Havertown, Pa.). The thrombolytic properties of the t-PA/scu-PA chimeras were evaluated in a hamster pulmonary embolism model using procedures for anesthesia and surgery described in detail elsewhere. 33 Briefly, a 50-,ll 1251-fibrin-labeled human plasma clot was produced in vitro and injected into the jugular vein of heparinized outbred hamsters (Pfd Gold, University of Leuven, Belgium). Thrombolytic agents or saline was infused intravenously over 60 minutes, and 30 minutes after the end of the infusion, the extent of clot lysis was determined as the difference between the radioactivity initially incorporated in the clot and the residual radioactivity in the lungs and the heart. Alternatively, bolus injections of rscu-PA and t-PA-AFE/scu-PA-e were given intravenously over 1 minute. Blood samples (0.2 ml) were drawn into trisodium citrate (0.011 M final concentration) just before the start of the infusion and 60 and 90 minutes later, or before and 1 and 90 minutes after the bolus injection.
Thrombolysis in Rabbits With Jugular Vein Thrombosis and in Baboons With Femoral Vein Thrombosis
The thrombolytic properties of rscu-PA, t-PA/scu-PA-s, t-PA/scu-PA-e, t-PA-AFE/scu-PA-e, t-PA-AK1VK2/scu-PA-e, and rt-PA were evaluated in a rabbit jugular vein thrombosis model using procedures for anesthesia and surgery as described in detail elsewhere. 35 In the present study, '~I-fibrin-labeled jugular vein thrombi were aged for 30 minutes, then the plasminogen activators were administered as a 10% bolus injection followed by continuous infusion of the remaining 90% dose over 4 hours via a contralateral marginal ear vein. Thrombolysis was quantitated 30 minutes after the end of the infusion by counting the residual radioactivity in the jugular vein segment.
The thrombolytic properties of rscu-PA and t-PA-AFE/scu-PA-e were then compared in baboons (Papio hamadraeus) with femoral vein blood clots using procedures for anesthesia and surgery as described in detail elsewhere. 36 Briefly, a 251I-fibrin-labeled blood clot was produced in an isolated femoral vein segment. The plasminogen activators were administered intravenously as a 10% bolus injection followed by continuous infusion of the remaining 90% dose over 2 hours via a brachial vein or, alternatively, as a 5-minute bolus injection. Thrombolysis was quantitated 30 minutes after the end of the infusion or 145 minutes after the bolus injection by determination of the residual radioactivity in the femoral vein segment.
Thrombolysis in Dogs With a Combined Femoral Vein Blood Clot and a Platelet-Rich Femoral Arterial Eversion Graft Thrombus
The arterial thrombosis model was modified from a rabbit femoral arterial eversion graft thrombosis model described elsewhere.37 Adult shepherd dogs weighing 15-25 kg were premedicated with 0.25 mg/kg fluanisone i.m., anesthetized with 30 mg/kg sodium pentobarbital i.v. followed by 60-mg boluses t-PA 1 . 1219 1220 Circulation Vol 84, No 3 September 1991 when needed, and were intubated and artificially ventilated. Cefacidal (1 g) was given intravenously. Catheters were inserted in the left jugular vein for blood sampling and in the brachial vein for infusion of drugs. The left carotid artery was exposed and isolated. A 3-cm segment of the left carotid artery was then excised, everted, and immersed in physiological saline. The left carotid artery was then cannulated for continuous blood pressure monitoring. The right femoral artery was exposed in the inguinal region, and side branches, when present, were ligated. The baseline blood flow in the right femoral artery was measured with an electromagnetic flow probe (Medelad, Deurne, Belgium). The everted segment from the left carotid artery was then inserted into the transected femoral artery by end-to-end anastomosis using 12-16 interrupted sutures with 7-0 nylon (DG Atraumatic, American Cyanamid Co., Danbury, Conn.). The microvascular clamps occluding the proximal and distal ends of the transected artery were then released. Blood flow was restored in all 23 dogs to approximately 20% of baseline flow. This was followed by spontaneous occlusion of the everted segment graft within 17±3 minutes (mean±SEM), which persisted for 60 minutes as determined by electromagnetic flow measurements. The surgical procedure was carried out under sterile conditions. The animal studies conform to the guiding principles of the American Physiological Society.
The venous blood clot was produced in the left femoral vein as previously described. 38 Briefly, the femoral vein was isolated between the inguinal ligament and the distal bifurcation and all side branches were carefully ligated except for a predominant musculocutaneous branch, which was cannulated. After introduction of a woolen thread into the lumen, a 4-cm segment of the femoral vein was isolated between two vessel clamps, emptied, and flushed with saline via the side branch catheter. The segment was then filled with a mixture of a trace amount of 125'-labeled human fibrinogen, 0.6-1.2 ml of fresh blood, and 2 units of a thrombin solution. The venous vessel clamps were released after the right femoral artery clot was stabilized for 60 minutes, and the infusion protocol was started approximately 1 minute later. The radioisotope content of the venous clot was calculated by subtracting, from the original amount of 1251 injected into the isolated vein segment, the radioisotope that was adsorbed on the cotton swabs placed around the vein segments, and radioiodine that was washed out from the thrombus into the bloodstream, as determined 1 minute after removal of the clamps. Two hours after the bolus injection of thrombolytic agents, the thrombosed segment of the femoral vein was ligated at both sides, removed, and its radioisotope content measured. The degree of clot lysis was determined as the residual radioactivity in the vein segment and expressed in percent of the radioactivity originally incorporated in the clot. An isotope recovery balance was expressed by comparing the sum of the total blood radioactivity at the end of the experiment (multiplied by three for extravascular distribution) and the radioactivity in the recovered thrombus with that originally present in the clot.
All animals received intravenous bolus injections of heparin (100 units/kg. hr for 3 hours) starting just before the release of the right femoral artery vessel clamps. Twenty-three dogs with stable arterial graft occlusion for 60 minutes were assigned to five study groups. The first 10 dogs were assigned to an intravenous bolus injection of 0.25 mg/kg of t-PA-AFE/scu-PA-e or rscu-PA. The last 10 dogs were given an intravenous bolus injection of 2.5 mg/kg ridogrel, a combined thromboxane synthase inhibitor and prostaglandin endoperoxide receptor antagonist, followed by an infusion of 2.5 mg/kg over 60 minutes, in combination with a bolus injection of 0.25 mg/kg of t-PA-AFE/scu-PA-e or rscu-PA. Three dogs used as controls without thrombolytic or antiplatelet agents were studied interspersed with the active treatment groups.
The recanalization time was taken as the time from the injection of thrombolytic agent or placebo until reflow of the occluded graft segment and was determined with the electromagnetic flow probe. The blood flow was continuously recorded during 3 hours to document reocclusion or stable reflow. Venous clot lysis was determined from the residual radioactivity in the thrombosed segment 120 minutes after the bolus injection of thrombolytic agent or placebo.
At the end of the experiment, the dogs were killed with an overdose of pentobarbital. The segments of the thrombosed or reperfused femoral arteries were fixed in Bouin reagent and embedded in paraffin. The segments were sectioned longitudinally, stained with hematoxylin and eosin, and evaluated microscopically.
Analysis of Thrombolysis Data
The thrombolytic potency (clot lysis versus dose) and the specific thrombolytic activity (clot lysis versus plasma antigen level) of the compounds in the hamster, rabbit, and baboon venous thrombosis models were determined in the following way: The mean values of the percent lysis (y) versus dose in milligrams of compound per kilogram of body weight (x), or of the percent lysis (y) versus steady-state plasma antigen level in micrograms per milliliter (x), were fitted with an exponentially transformed sigmoidal function lOOc y 1 +e -a(e-eb) using the statistical program GRAFIT (Erithacus Ltd., Middlesex, UK). The mean±SEM of the parameters c (maximal lysis in percent), b (dose in milligrams of compound per kilogram of body weight for the thrombolytic potency, or steady-state plasma antigen level in micrograms per milliliter for the specific thrombolytic activity, at which the rate of clot lysis is maximal), and z=(ac . eb)/4 (maximal rate of lysis expressed as percent lysis per milligram of compound per kilogram of body weight for the thrombolytic potency, or percent lysis per microgram per milliliter (4) Data represent mean±SEM with the number of experiments given in parentheses. *Antigen levels were determined at the end of a 1-hour infusion or at the end of a 1-minute bolus injection. steady-state plasma antigen level for the specific thrombolytic activity) were determined. In this equation, the parameter a represents the reciprocal of the dose administered (for the thrombolytic potency) or of the plasma antigen level (for the specific thrombolytic activity). The significance of the differences between these parameters was determined using the Student's t test.
The results of the dog experiments are expressed as mean+SEM. The significance of the differences between groups was compared using Fisher's exact test for categorical data or the Student's t test for paired or unpaired values. A Kruskal-Wallis nonparametric analysis of variance was performed39 on ranks of the ordered variable of femoral arterial patency (0, persistent occlusion; 1, cyclic reocclusion and reflow after initial recanalization; 2, persistent patency after initial recanalization) as determined with the electromagnetic blood flow probe.
This form of analysis of variance was selected because of the non-Gaussian distribution of the patency-state variables. Pharmacokinetic Properties of t-PA/scu-PA Chimeras The pharmacokinetic parameters of the disposition of the t-PA/scu-PA chimeras from blood were evaluated in hamsters, rabbits, and baboons after bolus injection of 0.1 or 0.25 mg/kg in groups of three or more animals. Concentrations of antigen in plasma were measured at different time intervals after intravenous bolus injection. The results were plotted on semilogarithmic paper and fitted with a sum of two exponential terms, C(t)=Ae`+Be-t by graphical curve peeling.40 In rabbits and baboons, disappearance of antigen from plasma was also monitored after the end of a continuous infusion of the plasminogen activators. The data describing the postinfusion disappearance of t-PArelated or u-PA-related antigen from plasma were fitted with a sum of two exponential terms, C(t)=Re`+SeCt by graphical curve peeling. The variables A and B were first calculated (assuming steady state at the end of the infusion) using the formulas A=RX0a/ko and B=SX0f3/k0, where X0 is the total administered dose and ko is the rate of infusion. Pharmacokinetic parameters were calculated from the coefficients A and B and exponents a and /8 using standard formulas derived by Gibaldi and Perrier.40 These pharmacokinetic parameters included initial half-life (in minutes), t/2a=1n2/a; Table 2 summarizes the thrombolytic properties of rscu-PA, t-PA/scu-PA-s, t-PA/scu-PA-e, t-PA-AFE/ scu-PA-e, t-PA-AK1V7K2/scu-PA-e, t-PA-AFEK1VK2/ scu-PA-e, and rt-PA. The infusions produced dosedependent clot lysis in the absence of extensive systemic fibrinogen or a2-antiplasmin consumption. The thrombolytic potencies and specific thrombolytic activities of the agents were compared by fitting of the dose-response data with an exponentially transformed sigmoidal function as described above. The fitted doseresponse curves for infusions of rscu-PA, t-PA-AFE/ scu-PA-e, and t-PA-/\KVK2/scu-PA-e are illustrated in Figure 2 , panels AI and BI. The values, expressed as mean+SEM of the parameters b and z of the fitted function, are summarized in Table 3 . The results indicate that t-PA/scu-PA-s and t-PA/scu-PA-e are not superior to rscu-PA. Unexpectedly, t-PA-AFE/scu-PA-e but not t-PA-AK1VK2/scu-PA-e or t-PA-AFEK1VK2/scu-PA-e had a significantly higher thrombolytic potency (percent lysis per milligram of compound per kilogram of body weight) than either rscu-PA or rt-PA, characterized by both a lower b value and a higher z value (p<0.01). However, the specific thrombolytic activity (percent lysis per microgram per milliliter steady-state plasma level) of t-PA-AFE/scu-PA-e was not different from that of rscu-PA, whereas that of t-PA-AK1VK2/scu-PA-e and t-PA-AFEK1VK2/ scu-PA-e was lower (higher b value and lower z value) than that of rscu-PA. Additional experiments with rt-PA revealed that rt-PA is more potent than rscu-PA in this animal model.
Bolus injections of rscu-PA and t-PA-AFE/scu-PA-e also produced dose-related clot lysis without extensive a2-antiplasmin consumption and fibrinogen breakdown ( Table 2) . Again, bolus t-PA-AFE/scu-PA-e had a markedly higher thrombolytic potency (characterized by a b value of 0.01 +0.003 mg/kg and a z value of 2,100±500% lysis per milligram per kilogram), as compared with bolus rscu-PA (b value of 0.50±0.06 mg/kg and a z value of 54±8% lysis per milligram per kilogram) (p<0.01 each).
Thrombolysis in Rabbits With Jugular Vein Thrombosis and Baboons With Femoral Vein Thrombosis
The thrombolysis results obtained with rscu-PA, t-PA-/\FE/scu-PA-e, t-PA-AK1VK2/scu-PA-e, and rt-PA in rabbits are summarized in Table 4 and illustrated in Figure 2 , panels All and BII. A dosedependent degree of clot lysis was obtained, and all plasminogen activators produced thrombolysis in the absence of extensive systemic fibrinolytic activation as evidenced by high residual fibrinogen and a2antiplasmin levels. The relative thrombolytic potencies and specific thrombolytic activities for the agents were determined from the parameters b and z of the exponentially transformed fitting function. The results are summarized in Table 3 . Again, the throm- bolytic potency of t-PA-AK1VK2/scu-PA-e was not superior to that of rscu-PA, whereas that of t-PA-AFE/scu-PA-e was significantly higher as evidenced by both a lower b value and a higher z value. The specific thrombolytic activity of t-PA-AFE/scu-PA-e was lower than that of rscu-PA as evidenced by both a higher b value and a lower z value. The thrombolysis results obtained in baboons are summarized in Table 5 and illustrated in Figure 2 , panels AIII and Bll. A dose-dependent degree of clot lysis was obtained in the absence of systemic fibrinogen breakdown and a2-antiplasmin depletion. The thrombolytic potency of t-PA-AFE/scu-PA-e was characterized by a significantly lower b value and by a higher z value than that of Saruplase (p=0.02) ( Table 3 ). The specific thrombolytic activity of rscu-PA could not be obtained by computer fitting of the data. Bolus injections of rscu-PA and t-PA-AFE/ scu-PA-e (Table 5) revealed an approximately fourfold higher thrombolytic potency of the latter.
Thrombolysis in Dogs With Combined Femoral Arterial and Venous Thrombosis
Femoral arterial eversion graft recanalization and reocclusion. The results of femoral arterial blood flow measurements after the insertion of the everted carotid artery segment into the transected femoral artery are summarized in Table 6 . In all 23 dogs, blood flow was restored after release of the vessel clamp and stabilized at 20-25% of baseline. Graft occlusion persisting for 60 minutes occurred in all dogs within 17±3 minutes (mean±SEM).
Bolus injection of 0.25 mg/kg t-PA-AFE/scu-PA-e in five dogs (group 1) was associated with reflow in all dogs with a time to recanalization of 26±8 minutes, but this was followed by cyclic reocclusion and reflow in four animals and persistent patency in one animal. Bolus injection of the same dose of rscu-PA in five dogs (group 2) was associated with persistent occlusion in three animals and with recanalization followed by cyclic reocclusion and reflow in two dogs after 31±12 minutes. When the 0.25 mg/kg bolus t-PA-AFE/scu-PA-e injection was combined with bolus injection of 2.5 mg/kg ridogrel followed by infusion of 2.5 mg/kg ridogrel over 1 hour (group 3), stable reperfusion persisting for 2 hours was observed in all five animals with a time to recanalization of 16+6 minutes. With a 0.25 mg/kg bolus injection of rscu-PA in combination with ridogrel (group 4), reflow was obtained in one of five dogs within 35 minutes, but this was followed by cyclic reocclusion and reflow. In three dogs, control without ridogrel and thrombolytic agent (group 5) arterial occlusion persisted throughout the observation period. The time course of the femoral artery recanalization in the individual animals is schematically represented in Figure 3 . The results of femoral arterial patency during the 2-hour observation period after the start of the infusion protocol, categorized as persistent occlusion, cyclic reocclusion and reflow after initial recanalization, or persistent patency after initial reflow, are summarized in Table 6 . Statistical analysis of the femoral arterial blood flow data showed no difference in blood flow after clamp release between groups 1 to 5 (p>0.1). The time to reflow in group 3 was not significantly different from that in group 1 (16±6 minutes versus 26+8 minutes, p=0.3). A Kruskal-Wallis analysis with patency status ordered in the sequence of persistent occlusion, cyclic reocclusion and reflow after initial recanalization, and persistent patency after initial reflow yielded a p value of 0.002 for overall differences between groups, p=0.042 for the difference between groups 1 and 2, p=0.014 for the difference between groups 1 and 3, and p=O0.004 for the difference between groups 3 and 4. The heart rate and blood pressure were not significantly different between the groups (data not shown).
Femoral vein clot lysis. The results of femoral vein clot lysis and isotope recovery are summarized in Table 6 . In the group given t-PA-AFE/scu-PA-e without ridogrel (group 1), the extent of apparent clot lysis was 90±4% compared with 36±3% lysis in group 2 with the same dose of rscu-PA (p<0.001). Combination of these agents with ridogrel did not significantly alter the extent of thrombolysis. The calculated isotope recovery balance ranged between 85% and 100% in all five groups. Hemostasis analysis. Template bleeding times (Table 7) measured before injection of study drugs averaged 2 or 3 minutes. Bleeding times did not change significantly with t-PA-AFE/scu-PA-e or rscu-PA alone but were prolonged to over 30 minutes during infusion of ridogrel and during the 1-hour follow-up period after the end of the ridogrel infusion. Ex vivo platelet aggregation, induced with either ADP or the combination of epinephrine and arachidonic acid, was unaltered with t-PA-AFE/scu-PA-e or rscu-PA alone (p>0.1) and was partially inhibited with ridogrel and t-PA-AFE/scu-PA-e or with ridogrel and rscu-PA. The platelet count did not change significantly in any of the groups.
The results of fibrinogen, a2-antiplasmin, activated partial thromboplastin time, and t-PA-AFE/scu-PAe-related or rscu-PA-related antigen levels are summarized in Table 8 . A dose of 0.25 mg/kg t-PA-AFE/ scu-PA-e in heparinized dogs did not cause fibrinogen or a2-antiplasmin consumption. Activated partial thromboplastin times were prolonged at least twofold in all experimental groups. Plasma levels of t-PA-AFE/scu-PA-e-related or rscu-PA-related antigen increased to 2.2 t,g/ml and 2.8 ,g/ml, respec- WS,A V.50,0l tively, 1 minute after the bolus injection and decreased to approximately 1 ,ug/ml and to less than 0.01 ,ug/ml, respectively, toward the end of the 2-hour observation period after the bolus injection. Pathological examination. The results of pathological analysis are summarized in Table 9 . The extent of arterial thrombosis was graded as occlusive thrombus, mural thrombus, and patent artery. The composition of the thrombus was identified as platelet-rich, erythrocyte-rich, or mixed with interlaced plateletrich and erythrocyte-rich thrombus. The persistently occlusive thrombus in animals given rscu-PA consisted of transluminal platelet-rich thrombus in four PR  5  MT  PR  4  1  OT  MPE  2  OT  MPE  3  OT  MPE  4  OT  MPE  5  OT  PR  5  1  OT  PR  2  OT  MPE  3 OT ER MT, mural thrombus; PR, platelet-rich thrombus; PT, partially occlusive thrombus; PA, patent artery; OT, occlusive thrombus; MPE, mixed thrombus with interlaced platelet-rich and erythrocyte-rich zones; ER, erythrocyte-rich thrombus. dogs and mixed thrombus in one dog. Reperfused arteries at 2 hours in the animals given t-PA-AFE/ scu-PA-e combined with ridogrel were devoid of thrombotic material in two animals and contained some residual platelet-rich thrombus in the other three dogs. Typical examples of everted segments are represented in Figure 4 .
Pharmacokinetic Properties of t-PA/scu-PA Chimeras
The plasma disappearance rates of t-PA-AFE/scu-PA-e-related or u-PA-related antigen after bolus injection of rscu-PA, t-PA-AFE/scu-PA-e, or t-PA-AK1VK2/scu-PA-e in hamsters, rabbits, baboons, and dogs are shown in Figure 5 . Table 10 summarizes relevant pharmacokinetic parameters describing the disposition of t-PA/scu-PA chimeras as well as rscu-PA and rt-PA from blood after bolus injection of 0.25 mg/kg in groups of three or four hamsters. rscu-PA has a rapid clearance of 1.8 ml/min as a result of a short initial t/2 of 2.0 minutes. rt-PA has a plasma clearance of 2.8 ml/min and an initial t/2 of 1.5 minutes. Both chimeras, t-PA/scu-PA-s and t-PA/ scu-PA-e, have a comparably fast clearance of 1.1 ml/min and an initial plasma half-life of 1.4 minutes. The three variant chimeras, t-PA-AFE/scu-PA-e, t-PA-AK17K2/scu-PA-e, and t-PA-AFEK1VK2/scu-PA-e, have a threefold to fourfold longer initial half-life (8 minutes) and a slower clearance (0.3-0.7 ml/min) than rscu-PA, rt-PA, or t-PA/scu-PA-e. Table 10 also summarizes relevant pharmacokinetic parameters describing the disposition of rscu-PA, t-PA-AFE/scu-PA-e, or rt-PA from blood after bolus injection of 0.1 mg/kg in groups of three or four rabbits. rscu-PA has a clearance of 26 ml/min as a result of an initial t/2 of 1.7 minutes compared with a clearance of 37 ml/min and an initial t1/2 of 1.1 minute for rt-PA. t-PA-AFE/scu-PA-e has an initial t/2 of 7 minutes and a 10to 15-fold slower clearance (2.6 ml/min) than rscu-PA or rt-PA. In addition, antigen concentration in plasma was monitored after the end of an infusion over 4 hours of t-PA-AFE/scu-PA-e at a dose of 0.13, 0.25, and 0.50 mg/kg and t-PA-AK1VK2/scu-PA-e at a dose of 0.25, 0.50, or 1.0 mg/kg. These pharmacokinetic parameters are summarized in Table 11 . For t-PA-AFE/scu-PA-e, the clearance of 1.1-2.2 ml/min is somewhat smaller than the value of 2.6 ml/min derived from the bolus injection. The initial and terminal t1/2 values of 8-12 minutes and 60-80 minutes, respectively, of the postinfusion disposition of t-PA-related antigen for plasma are very similar to the half-lives of 7 and 65 minutes after bolus injection. Table 10 summarizes the pharmacokinetic parameters obtained after bolus injection of 0.25 mg/kg t-PA-AFE/scu-PA-e in three baboons and of 0.25 mg/kg or 1.0 mg/kg rscu-PA in two baboons each. Again, the plasma clearance of t-PA-AFE/scu-PA-e is more than 20-fold slower than that of rscu-PA, whereas the initial t½/2 is about fivefold longer. Similarly, as summarized in Table 11 , after the end of a 2-hour infusion of thrombolytic agent, the initial tl/2 of rscu-PA was 2.5-2.9 minutes and plasma clearance 330-340 ml/min compared with an initial t1/2 of 10-14 minutes and plasma clearance of 25-43 ml/ min for t-PA-AFE/scu-PA-e. Table 10 summarizes the pharmacokinetic parameters obtained after bolus injection of 0.25 mg/kg t-PA-AFE/scu-PA-e or rscu-PA in three dogs each. Plasma clearances again differed more than 15-fold.
Discussion The results of the present study, together with those of earlier in vivo studies with t-PA and with domain deletion mutants of t-PA4'-45 shed some new light on the mechanism of action of t-PA and scu-PA. Indeed, deletion of the F and E domains of t-PA markedly delays its clearance,41-45 partially abolishes its fibrin affinity,43-47 and markedly reduces its specific thrombolytic activity (percent clot lysis per unit steady-state concentration of plasminogen activator in blood),41 resulting in unaltered or at best marginally improved thrombolytic potency in vivo (percent lysis per unit dose administered per kilogram of body weight).41t4248 Partial restoration of the fibrin affinity by exchange of K, of t-PA with a second copy of K2 improves the thrombolytic potency twofold in the hamster pulmonary embolism model, but these variants still have a markedly reduced specific thrombolytic activity.49 Similar structural alterations in chimeras of the A-chain of t-PA and the protease domain of scu-PA have totally different functional consequences. Indeed, whereas the deletion variant t-PA-AFE/scu-PA-e of the present study also has a markedly reduced clearance, it has a significantly improved thrombolytic potency as a result of relatively maintained specific thrombolytic activity. The variants t-PA-AK,'VK2/scu-PA-e and t-PA-A FEK1VK2/scu-PA-e, which have a significantly higher lysine affinity and a marginally higher fibrin affinity than t-PA-AFE/scu-PA-e (Reference 29, Table 1 ), both appear to have a markedly reduced specific thrombolytic activity. These findings indicate that targeting of the protease domain of u-PA to a fibrin clot with the use of the structural domains of the A-chain of t-PA responds differently than targeting of the t-PA protease region by the same domains. Probably a correct steric assembly of t-PA and plasminogen at the fibrin surface is crucial for efficient catalysis. Targeting of u-PA to the t-PA binding sites on the fibrin surface may not produce the productive ternary complex,5 resulting in a reduced catalytic efficiency. Thus, the increased thrombolytic potency of t-PA-AFE/scu-PA-e appears to be primarily or exclusively due to its delayed clearance and not to fibrin targeting.
The improved in vivo thrombolytic potency of t-PA-AFE/scu-PA-e could not have been predicted or anticipated from the in vitro characteristics of this molecule. 18, 27, 29 Indeed, the specific activity, catalytic efficiency for plasminogen activation, and stimulation by fibrin are not significantly different from those of wild-type scu-PA or from those of the other chimeras. Binding to fibrin and to lysine-Sepharose is in fact lower for t-PA-AFE/scu-PA-e than for the other chimeras, whereas their fibrinolytic potency and fibrin specificity in human plasma in vitro are comparable. This suggests that either the fibrin affinity of such chimeras has only a marginal effect on their in vitro fibrinolytic potency or the static in vitro plasma clot lysis system is not able to reveal differences that might be significant in vivo. Furthermore, determination of the pharmacokinetic parameters also did not allow predictions on the thrombolytic potency. t-PA-AK1VK2/scu-PA-e and t-PA-AFEK1VK2/scu-PA-e both have a significantly reduced clearance (comparable with that of t-PA-AFE/scu-PA-e); however, they do not have a higher thrombolytic potency than scu-PA. This appears to be due to a markedly reduced in vivo specific thrombolytic activity reminiscent of that observed with domain deletion mutants of t-PA such as t-PA-AFE. 41 The lack of correlation between the in vitro properties of these t-PA/u-PA chimeras, their pharmacokinetics, and their specific thrombolytic activity indicates that, at least for this type of molecules, extrapolation of biochemical properties to potential clinical use is not warranted. Such extrapolations, however, have formed the basis for intense research activity into improved thrombolytic agents. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] Fur- thermore, our data indicate that the approach to obtain improved thrombolytic agents by endowing the scu-PA molecule with fibrin affinity by fusion with t-PA domains does not work. Nevertheless, t-PA-AFE/scu-PA-e, which on the basis of its biochemical properties would have been predicted to be the least interesting molecule, may hold the most promise for clinical use. All chimeras investigated in the present study, as well as rscu-PA itself, are relatively fibrin-specific thrombolytic agents that can produce marked clot lysis without extensive associated fibrinogen breakdown and a2-antiplasmin consumption. This is not surprising, in view of the proposed mechanism of fibrin specificity of scu-PA, which is not mediated via binding to fibrin but depends on the single-chain structure of the u-PA moiety.7
Recombinant chimeras of t-PA and scu-PA constitute one approach to potential improvement of the thrombolytic potency of thrombolytic agents. Alternative approaches might consist of site-directed mutagenesis of the native molecules to alter their pharmacological profiles or of targeting of plasminogen activators to clots via monoclonal antibodies directed against fibrin or activated platelets. 50 Engineered plasminogen activators with an increased thrombolytic potency toward erythrocyte-rich and fibrin-rich whole blood clots may not necessarily constitute superior agents for the recanalization of coronary arteries, which are frequently occluded with platelet-rich thrombus51,52 that is resistant to dispersion with thrombolytic agents3753 and are prone to reocclusion with platelet-rich thrombus after recanalization.54 Indeed, the resistance to recanalization and the tendency to reocclusion appear to be plateletmediated phenomena that may be overcome with the use of potent specific antiplatelet agents55,56 or thrombin inhibitors. 57 Therefore, the effects of t-PA-AFE/scu-PA-e and rscu-PA were compared in a combined platelet-rich arterial and erythrocyte/fibrin-rich venous thrombosis model in the dog. The agents were studied alone ,. produced in the present model is very resistant to dispersion with thrombolytic agents. Indeed, recanalization was only obtained in three of 10 dogs with 0.25 mg/kg rscu-PA, and this was consistently associated with cyclic reocclusion and reflow. However, 0.25 mg/kg t-PA-AFE/scu-PA-e produced recanalization in all 10 dogs, although this was only main- tained in the presence of concomitant administration of ridogrel. The mechanism of the enhancing effect of t-PA-AFE/scu-PA-e combined with ridogrel on the lysis of the platelet-rich thrombus is not fully understood. It is possible that t-PA-AFE/scu-PA-einduced activation of the fibrinolytic system dissolves the fibrin (which holds the platelet clumps together) while ridogrel prevents deposition of new platelets on the residual thrombus and the adventitial surfaces.
These results add to the accumulating evidence that thrombolytic agents in combination with antiplatelet agents can overcome the resistance of platelet-rich thrombus to recanalization and prevent cyclic reocclusion and reflow after initial recanalization. In addition, the present results confirm that the inhibition of platelet aggregation does not alter the extent of venous clot lysis, which is primarily determined by the dose and potency of the plasminogen activator.59 Bleeding complications, as witnessed by the prolongation of the bleeding time with ridogrel, remain a reason for concern, and strategies to accelerate lysis and prevent reocclusion with less prolongation of the bleeding time need to be explored further.
Conclusion
Our study suggests that, provided these observations can be extrapolated to humans, t-PA-AFE/scu-PA-e may constitute a useful thrombolytic agent for coronary arterial recanalization in patients with acute myocardial infarction. Indeed, its delayed clearance with relatively preserved specific thrombolytic activity may allow a significant reduction of the total amount required for thrombolytic therapy and may allow its administration by bolus injection.
